Overview

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2024-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC